Emily Becker

List of publications:

BibTeX-Download

Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Publications

(8)

Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease (2023) Schulze L, Becker E, Dedden M, Liu L, Van Passen C, Mohamed Abdou M, Müller T, et al. Journal article Anti-beta 7 integrin treatment impedes the recruitment on non-classical monocytes to the gut and delays macrophage-mediated intestinal wound healing (2023) Sommer K, Heidbreder K, Kreiß L, Dedden M, Paap EM, Wiendl M, Becker E, et al. Journal article, Original article IL-3 receptor signalling suppresses chronic intestinal inflammation by controlling mechanobiology and tissue egress of regulatory T cells. (2023) Ullrich K, Derdau J, Baltes C, Battistella A, Rosso G, Uderhardt S, Schulze L, et al. Journal article Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells (2022) Schweda A, Becker E, Wiendl M, Atreya R, Atreya I, Müller T, Neurath M, Zundler S Journal article Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets (2022) Becker E, Schweda A, Ullrich K, Voskens C, Atreya R, Müller T, Atreya I, et al. Journal article Expression and function of α4β7 integrin predict the success of vedolizumab treatment in inflammatory bowel disease (2022) Schneider I, Allner C, Mühl L, Melde M, Lissner D, Mantzivi E, Glauben R, et al. Journal article α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis (2021) Melde M, Müller T, Schneider IHF, Geppert CI, Mühl L, Besendorf L, Allner C, et al. Journal article Residual homing of alpha 4 beta 7-expressing beta 1(+)PI16(+) regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab (2021) Becker E, Dedden M, Gall C, Wiendl M, Ekici AB, Schulz-Kuhnt A, Schweda A, et al. Journal article